Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists

James S. Lewis, Beth Beadle, Justin A. Bishop, Rebecca D. Chernock, Carol Colasacco, Christina Lacchetti, Joel Todd Moncur, James W. Rocco, Mary R. Schwartz, Raja R. Seethala, Nicole E. Thomas, William H. Westra, William C. Faquin

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Context.—Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective.—To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design.—The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results.—The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions.—Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.

Original languageEnglish (US)
Pages (from-to)559-597
Number of pages39
JournalArchives of Pathology and Laboratory Medicine
Volume142
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Neck
Head
Guidelines
Carcinoma
Squamous Cell Carcinoma
Biomarkers
Radiation Oncology
Medical Oncology
Molecular Pathology
Pathologists
Neoplasms
Immunohistochemistry
Staining and Labeling
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists. / Lewis, James S.; Beadle, Beth; Bishop, Justin A.; Chernock, Rebecca D.; Colasacco, Carol; Lacchetti, Christina; Moncur, Joel Todd; Rocco, James W.; Schwartz, Mary R.; Seethala, Raja R.; Thomas, Nicole E.; Westra, William H.; Faquin, William C.

In: Archives of Pathology and Laboratory Medicine, Vol. 142, No. 5, 01.05.2018, p. 559-597.

Research output: Contribution to journalArticle

Lewis, JS, Beadle, B, Bishop, JA, Chernock, RD, Colasacco, C, Lacchetti, C, Moncur, JT, Rocco, JW, Schwartz, MR, Seethala, RR, Thomas, NE, Westra, WH & Faquin, WC 2018, 'Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists', Archives of Pathology and Laboratory Medicine, vol. 142, no. 5, pp. 559-597. https://doi.org/10.5858/arpa.2017-0286-CP
Lewis, James S. ; Beadle, Beth ; Bishop, Justin A. ; Chernock, Rebecca D. ; Colasacco, Carol ; Lacchetti, Christina ; Moncur, Joel Todd ; Rocco, James W. ; Schwartz, Mary R. ; Seethala, Raja R. ; Thomas, Nicole E. ; Westra, William H. ; Faquin, William C. / Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists. In: Archives of Pathology and Laboratory Medicine. 2018 ; Vol. 142, No. 5. pp. 559-597.
@article{60800e1ac1244415ac6373c1843d8b03,
title = "Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists",
abstract = "Context.—Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective.—To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design.—The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results.—The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70{\%} nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions.—Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.",
author = "Lewis, {James S.} and Beth Beadle and Bishop, {Justin A.} and Chernock, {Rebecca D.} and Carol Colasacco and Christina Lacchetti and Moncur, {Joel Todd} and Rocco, {James W.} and Schwartz, {Mary R.} and Seethala, {Raja R.} and Thomas, {Nicole E.} and Westra, {William H.} and Faquin, {William C.}",
year = "2018",
month = "5",
day = "1",
doi = "10.5858/arpa.2017-0286-CP",
language = "English (US)",
volume = "142",
pages = "559--597",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Human papillomavirus testing in head and neck carcinomas guideline from the college of American pathologists

AU - Lewis, James S.

AU - Beadle, Beth

AU - Bishop, Justin A.

AU - Chernock, Rebecca D.

AU - Colasacco, Carol

AU - Lacchetti, Christina

AU - Moncur, Joel Todd

AU - Rocco, James W.

AU - Schwartz, Mary R.

AU - Seethala, Raja R.

AU - Thomas, Nicole E.

AU - Westra, William H.

AU - Faquin, William C.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Context.—Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective.—To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design.—The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results.—The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions.—Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.

AB - Context.—Human papillomavirus (HPV) is a major cause of oropharyngeal squamous cell carcinomas, and HPV (and/or surrogate marker p16) status has emerged as a prognostic marker that significantly impacts clinical management. There is no current consensus on when to test oropharyngeal squamous cell carcinomas for HPV/p16 or on which tests to choose. Objective.—To develop evidence-based recommendations for the testing, application, interpretation, and reporting of HPV and surrogate marker tests in head and neck carcinomas. Design.—The College of American Pathologists convened a panel of experts in head and neck and molecular pathology, as well as surgical, medical, and radiation oncology, to develop recommendations. A systematic review of the literature was conducted to address 6 key questions. Final recommendations were derived from strength of evidence, open comment period feedback, and expert panel consensus. Results.—The major recommendations include (1) testing newly diagnosed oropharyngeal squamous cell carcinoma patients for high-risk HPV, either from the primary tumor or from cervical nodal metastases, using p16 immunohistochemistry with a 70% nuclear and cytoplasmic staining cutoff, and (2) not routinely testing nonsquamous oropharyngeal carcinomas or nonoropharyngeal carcinomas for HPV. Pathologists are to report tumors as HPV positive or p16 positive. Guidelines are provided for testing cytologic samples and handling of locoregional and distant recurrence specimens. Conclusions.—Based on the systematic review and on expert panel consensus, high-risk HPV testing is recommended for all new oropharyngeal squamous cell carcinoma patients, but not routinely recommended for other head and neck carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=85046682037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046682037&partnerID=8YFLogxK

U2 - 10.5858/arpa.2017-0286-CP

DO - 10.5858/arpa.2017-0286-CP

M3 - Article

C2 - 29251996

AN - SCOPUS:85046682037

VL - 142

SP - 559

EP - 597

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -